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ABSTRACT: The purpose of this study was to assess the clinical value of a novel DropOut model for 
detecting and segmenting brain metastases, in which a neural network is trained on four distinct MRI 
sequences using an input dropout layer, thus simulating the scenario of missing MRI data by training on 
the full set and all possible subsets of the input data. This retrospective, multi-center study, evaluated 165 
patients with brain metastases. A deep learning (DL) based segmentation model for automatic 
segmentation of brain metastases, named DropOut, was trained on multi-sequence MRI from 100 
patients, and validated/tested on 10/55 patients. The segmentation results were compared with the 
performance of a state-of-the-art DeepLabV3 model. The MR sequences in the training set included pre- 
and post-gadolinium (Gd) T1-weighted 3D fast spin echo, post-Gd T1-weighted inversion recovery (IR) 
prepped fast spoiled gradient echo, and 3D fluid attenuated inversion recovery (FLAIR), whereas the test 
set did not include the IR prepped image-series. The ground truth segmentations were established by 
experienced neuroradiologists. The results were evaluated using precision, recall, Dice score, and receiver 
operating characteristics (ROC) curve statistics, while the Wilcoxon rank sum test was used to compare 
the performance of the two neural networks. The area under the ROC curve (AUC), averaged across all test 
cases, was 0.989±0.029 for the DropOut model and 0.989±0.023 for the DeepLabV3 model (p=0.62). The 
DropOut model showed a significantly higher Dice score compared to the DeepLabV3 model (0.795±0.105 
vs. 0.774±0.104, p=0.017), and a significantly lower average false positive rate of 3.6/patient vs. 
7.0/patient (p<0.001) using a 10mm3 lesion-size limit. The DropOut neural network, trained on all possible 
combinations of four MRI sequences, may facilitate accurate detection and segmentation of brain 
metastases on a multi-center basis, even when the test cohort is missing MRI input data. 
 
Keywords: Deep Learning, Segmentation, Brain Metastases, Multi-sequence MRI   
  
 
*Co-first authorship (alphabetic order) 
†These authors contributed equally to this work (alphabetic order) 
 
1Department for Diagnostic Physics, Oslo University Hospital, Norway; 2Department of Radiology, Stanford University, 
USA; 3Department of Biomedical Data Science, Stanford University, USA; 4Department of Radiology and Nuclear Medicine, 
Oslo University Hospital, Norway; 5Department of Oncology, Oslo University Hospital, Norway  
 
Corresponding Author: Greg Zaharchuk, Department of Radiology, Stanford University, School of Medicine, 1201 Welch 
Road, Stanford, California 94305-5488, USA. Phone: (650) 736-6172, Fax: (650) 723-9222. Email: gregz@stanford.edu. 
INTRODUCTION 
Advances in artificial intelligence (AI) are suggesting the 
possibility of new paradigms in healthcare and are 
particularly well-suited to be adopted by radiologists (1–4). 
In recent years, there has been significant effort in utilizing 
the next-generation AI technology, coined deep learning, 
to learn from labeled magnetic resonance imaging (MRI) 
data (5–7). One key advantage of AI-based radiology is the 
automatization and standardization of tedious and time-
consuming tasks, most clearly exemplified in the tasks 
surrounding detection and segmentation (8–10). Several 
deep learning approaches have successfully been 
developed and tested for automatic segmentation of 
gliomas (11), thanks in part to the publicly available Brain 
Tumor Segmentation (BraTS) dataset (12). In recent years, 
studies have also shown the potential of AI-based 
segmentation in patient cohorts comprising tumor 
subtypes, such as brain metastases, which may pose a 
greater challenge in terms of segmentation performance 
given their wide range of sizes and multiplicity (13, 14). In 
a recent study, we trained a fully convolution neural 
network (CNN) for automatic detection and segmentation 
of brain metastases using multi-modal MRI (15). While our 
DL-approach showed high performance, the robustness 
and clinical utility needs to be challenged in order to fully 
understand its strengths and limitations. In fact, many AI-
based segmentation studies are limited in terms of 
generalizability in that the algorithms are trained and 
tested on single-center patient cohorts. In some studies, 
the training- and test-sets are even limited to a single 
magnetic field strength, a single vendor, and/or a single 
scanner for data acquisition. A key step towards 
understanding the generalizability and clinical value of any 
deep neural network is by training and testing using real-
world multicenter data. Another limitation of these AI-
based segmentation networks is that they are trained on a 
distinct set of MRI contrasts, which limits the use of the 
networks to sites acquiring the same sequences. However, 
deep neural networks should be able to handle missing 
model inputs.  
 To this end, this work tested a novel AI-based 
segmentation model, called DropOut, in which a neural 
network with an input dropout layer is trained on the full 
set of four distinct MRI sequences, as well as every possible 
subset of the input channels. The DropOut network was 
tested on a patient cohort missing one of the four input 
sequences used for training. To evaluate this network’s 
performance, a second neural network was trained and 
tested using state-of-the-art architecture without applying 
the DropOut strategy, i.e. only trained on the limited 
sequences corresponding to those in the test set.  We 
hypothesize that the DropOut model will yield 
segmentation performance comparable to that of a state-
of-the-art segmentation network, while at the same time 
being robust towards missing input data and allow it to 
generalize to multicenter MRI data.  
MATERIALS AND METHODS 
Patient Population 
This retrospective, multi-center study was approved by our 
Institutional Review Board. The patient cohort consisted of 
a total of 165 patients with brain metastases, enrolled 
from two different hospitals, hereinafter referred to as 
‘Hospital A’ and ‘Hospital B’. From Hospital A, MRI data 
from a total of 100 patients were acquired and used for 
neural network training.  A total of 65 patients from 
Hospital B were used for validation and testing.  
Inclusion criteria for the training data included the 
presence of known or possible metastatic disease (i.e., 
presence of a primary tumor), no prior surgical or radiation 
therapy, and the availability of all required MR imaging 
sequences (see below). Only patients with ≥ 1 metastatic 
lesion were included. Mild patient motion was not an 
exclusion criterion. For the validation and test data, we 
used MRI data from an ongoing clinical study entitled 
TREATMENT (NCT03458455) conducted at Hospital B.  To 
be eligible for inclusion, patients had to receive 
stereotactic radiosurgery (SRS) for at least one brain 
metastasis measured at a minimum of 5 mm in one 
direction, be untreated or progressive after systemic or 
local therapy, have confirmed non-small-cell lung cancer 
(NSCLC) or malignant melanoma, be ≥18 years of age; have 
an Eastern Cooperative Oncology Group performance 
status score ≤1, and have a life expectancy >6 weeks. 
Details on the patient cohorts are shown in Table 1.  
 
Imaging Protocol 
For the training set, imaging was performed on both 1.5T 
(n=7; SIGNA Explorer and TwinSpeed, GE Healthcare, 
Chicago, IL) and 3T (n=93; Discovery 750 and 750w and 
SIGNA Architect, GE Healthcare, Chicago, IL, USA; Skyra, 
Siemens Healthineers, Erlangen, Germany) clinical 
scanners. The imaging protocol included pre- and post-
Gadolinium (Gd) T1-weighted 3D fast spin echo 
(CUBE/SPACE), post-Gd T1-weighted 3D axial inversion 
recovery prepped fast spoiled gradient-echo (IR-FSPGR) 
(BRAVO/MPRAGE), and 3D CUBE/SPACE fluid-attenuated 
inversion recovery (FLAIR). For Gd-enhanced imaging, a 
dose of 0.1 mmol/kg body weight of gadobenate 
dimeglumine (MultiHance, Bracco Diagnostics, Princeton, 
New Jersey) was intravenously administered. 
Table 1: Patient demographics   
 Hospital A Hospital B 
# of patients 100 65 
Gender 71 F / 29 M 35 F / 30 M 
Mean age (range) 64 (32 – 92) 65 (32 – 86) 
Primary cancer:    
Lung 66 45 
Skin/melanoma 4 20 
Breast 26 - 
Genitourinary 2 - 
Gastrointestinal 2 - 
Table 2:  Overview of MRI pulse sequences and key imaging parameters  
Technique 3D T1 BRAVO Pre/Post 3D T1 CUBE/SPACE 3D FLAIR 
   
Hospital A Data 
TR (ms) * 12.02 / 8.24 550 / 602 6000 
TE (ms)* 5.05 / 3.24 9.54 / 12.72 119 / 136 
Flip angle* 20 / 13 90 90 
FOV (mm2) 240×240 250×250 240×240 
Inversion time (ms) * 300 / 400 - 1880 / 1700 
Acquisition matrix 256×256 256×256 256×256 
Slice thickness (mm) 1 1 1 – 1.6 
# of slices 160 270 – 320 270 – 320 
Slice acquisition plane Axial Sagittal Sagittal 
   
Hospital B Data** 
TR (ms)  – 700 5000 
TE (ms) – 12 387 
Flip angle – 120 120 
FOV (mm2) – 230×230 230×230 
Inversion time (ms)  – – 1800 
Acquisition matrix – 256×256 256×256 
Slice thickness (mm) – 0.9 0.9 
# of slices – 192 208 
Slice acquisition plane – Sagittal Sagittal 
TR = repetition time, TE = echo time, FOV = field-of-view, BRAVO – T1-weighted inversion recovery prepped fast spoiled 
gradient-echo, CUBE/SPACE – T1-weigthed fast spin-echo, FLAIR – fluid attenuated inversion recovery. 
* In case of varying parametric values between field strength, ’/’ notation is given (1.5T / 3T). 
** Note that the Hospital B data is missing 3D T1 BRAVO images 
For the test set, imaging (n=65) was performed on a clinical 
3T Skyra scanner (Siemens Healthineers, Erlangen, 
Germany). The imaging protocol included pre- and post-Gd 
T1-weighted 3D fast spin echo (SPACE) and 3D T2-
weighted FLAIR. All sequences with key imaging 
parameters are summarized in Table 2.  
 
Image pre-processing and segmentation 
For the training data, ground truth segmentations were 
established by two neuroradiologists with 9 and 3 years of 
experience by manually delineating and cross-checking 
regions of interests (ROIs) for every Gd-enhancing 
metastatic lesion. The lesions were outlined on each slice 
on the post-Gd 3D T1-weighted IR-FSPGR sequence, with 
additional guidance from the 3D FLAIR and the post-Gd 3D 
T1-weighted spin echo data using the OsiriX MD software 
package (Version 8.0, Geneva, Switzerland). 
 For the test data, ground truth segmentations of 
Gd-enhancing metastatic lesions were manually drawn on 
post-Gd 3D T1-weighted spin echo data by two radiologists 
with 14 and 5 years of relevant experience. Delineations 
were performed using the nordicICE software package 
(NordicNeuroLab, Bergen, Norway).  
 All imaging series were co-registered into one 
common anatomical space. For the training data, pre- and 
post-Gd 3D T1-weighted spin echo data and FLAIR were co-
registered to the post-Gd 3D T1-weighted IR-FSPGR, 
whereas for the test data, the post-Gd 3D T1-weighted spin 
echo images was used as the reference series for the pre-
Gd 3D T1-weighted spin echo data and FLAIR.  Prior to 
network training, a defacing procedure was applied to 
anonymize all imaging data using an in-house algorithm 
(MATLAB R2017a version 9.2.0, MathWorks Inc. Natick, 
MA). 
 
Neural Network Details 
The neural networks used in this study were based on the 
DeepLab V3 architecture (16), and the modifications and 
training strategies are detailed in a recent work (17). In 
particular, this study utilized and trained a ‘input-level 
integration dropout’ network, referred to as the DropOut 
model (Figure 1). This model was trained on patients from 
Hospital A, using 5 slices from the four aforementioned 
pulse sequences as input. These were all stacked together 
in the color channel, resulting in an image tensor of shape 
256x256x20 as the model input. The network was trained 
by utilizing a pulse-sequence level dropout; replacing the 
full 5 slices of any given pulse sequence with an empty 
tensor of 0's during training, thus enabling the network to 
handle missing MRI pulse sequence input during inference. 
This yields a network trained on a single data center with a 
superset of pulse sequences to what may be used in 
practice. 
A key mathematical note is that when pulse 
sequences are censored, the remaining sequences must be 
multiplied by a constant value to keep the pixel statistics 
relatively constant. For example, if a single pulse sequence 
is censored, the remaining three pulse sequence inputs are 
multiplied by a value of 4/3.  If two pulse sequences are 
censored, the remaining pulse sequences are multiplied by 
2 (= 4/2).  Thus, when inference was performed on patients 
from Hospital B, having only three of the four total pulse 
sequences, the corresponding slices of the ‘missing’ pulse 
sequence was defined as an empty 0-tensor, while the 
available three pulse sequences were multiplied by 4/3. 
To evaluate the segmentation performance of the 
DropOut model, a second neural network was trained and 
tested using the state-of-the-art DeepLab V3 architecture 
without applying the input-level dropout strategy, and 
only trained on the complete set of sequences matching 
that of the test set from Hospital B (i.e. excluding the post-
Gd 3D T1-weighted IR-FSPGR sequence).  
 All patients from Hospital A were used for 
training, while the patients from Hospital B were divided 
into training and validation sets, giving a final breakdown 
100 training cases, 10 validation cases, and 55 test cases. 
All training was done on a system with two NVIDIA GTX 
1080Ti GPUs. 
Statistical Analysis 
The networks’ ability to detect metastatic lesions on a 
voxel-by-voxel basis was evaluated using receiver 
operating characteristic (ROC) curve statistics, measuring 
the area under the ROC curve (AUC) for each patient in the 
test set. Further, the optimal probability threshold for 
including a voxel within the metastatic lesion was 
determined using the Youden index from the ROC statistics 
on the validation set. Using this threshold, the networks 
segmentation performance was further evaluated by 
estimating the precision- and recall-values, as well as the 
Dice similarity score (also known as the F1 score).  
In addition to evaluating the neural networks’ 
ability to detect metastatic tissue voxels, performance was 
also evaluated on a lesion-by-lesion basis by calculating the 
number of false positive (FP) per case. The FP was 
determined by multiplying the ground truth maps and the 
thresholded probability maps and counting the number of 
overlapping objects in the resulting binary image using a 
connecting component approach. Voxels were considered 
connected if their edges or corner touch.  The number of 
FP was determined both without any size criterion, as well 
as only considering objects ≥ 10 mm3 (roughly 2 mm in 
linear dimension) as a detected lesion. 
Finally, the Wilcoxon rank sum test was used to 
compare the performance of the DropOut model and the 
DeepLabV3 network. A statistical significance level of 5% 
was used. All statistical analyses were performed using 
MATLAB R2017a version 9.2.0 (MathWorks Inc. Natick, 
MA).  
 
RESULTS 
The total time used for training was approximately 20 
hours for both the DropOut model and the DeepLabV3 
network. For processing a test case using the DropOut 
model, the forward pass on a system with two NVIDIA GTX 
1080Ti GPUs took approximately 250 ms per slice.  
Figure 2 show six example cases demonstrating 
the resulting probability maps, as well as maps 
representing the performance in terms of true positive, 
false positive, and false negative, as an overlay on the post-
Gd 3D T1-weighted spin echo image series.  
Figure 1: Diagram showing the DeepLab V3 based segmentation network used in this study. Five contiguous axial 
slices of each of the four pulse sequences (BRAVO, pre- and post-Gd CUBE, and T2-weighted FLAIR) are concatenated 
in the color-channel dimension to create an input tensor with channel dimension 20.  This is fed into a DeepLab V3 
based network to predict the segmentation on the center slice. 
The metrics showing the segmentation performance of the 
Figure 2: Examples in representative test set cases showing the segmentation predictions from the [B] DeepLab V3 
model and the [C] DropOut method. The image mosaic shows the predictions as probability maps (voxel-wise ranging 
from 0 to 1 as indicated by the color bar) and performance maps classified as true negative, false positive, and false 
negative as specified by the color code. All maps are shown as overlays on a post-Gd 3D T1-weighted image series 
[A]. The cases shown here are [first row] a 65-year-old female with malignant melanoma, [second row], 73-year-old 
male with non-small cell lung cancer (NSCLC), [third row] 66-year-old male with NSCLC, [fourth row] 44-year-old 
female with NSCLC, [fifth row] 64-year-old female with NSCLC, and [sixth row] 73-year-old male with NSCLC. The blue 
arrows indicate true positive lesions, while yellow arrows indicate false positive lesions. Note that in the bottom three 
cases, the DeepLab V3 returns several false positive lesions which are not reported by the DropOut method, thus 
reflecting the results indicating a superior performance on false positive rate by the DropOut method.  
DropOut model and the DeepLabV3 network are 
summarized in Table 3.  Both the DropOut model and the 
DeepLab v3 network show a high voxel-wise detection 
accuracy, yielding an AUC, averaged across all test cases, 
of 0.989 ± 0.029 and 0.989 ± 0.029 (NS, p=0.620), 
respectively (Figure 3). 
Based on the ROC analysis on the validation set, 
an optimal probability threshold for including a voxel as a 
metastasis was set to 0.76 for the DropOut model, and 
0.87 for the DeepLab V3. Using these thresholds, the 
DropOut model demonstrated a significantly higher Dice 
score (0.795 ± 0.104) compared to the DeepLab network 
(0.774 ± 0.104) (p=0.017). The average recall and precision 
values were also higher for the DropOut model, but this 
difference was not statistically significant (Table 2).  
 On a per-lesion basis, and without any lesion-size 
limit, the DropOut model showed an average FP of 
12.3/patient, which was significantly lower that the 
DeepLabV3 network (26.3/patient, p<0.001). By applying a 
lesion-size limit of 10 mm3, the DropOut model 
demonstrated an average FP of 3.6/patient, also 
significantly lower that the DeepLabV3 (7.0/patient, 
p<0.001) (Figure 4). 
 
DISCUSSION 
Detection and segmentation of brain metastases on 
radiographic images sets the basis for clinical decision 
making and patient management. Precise segmentation is 
crucial for several steps in the clinical workflow such as 
treatment decision, radiation planning and assessing 
treatment response, and must therefore be performed 
with the utmost accuracy. Considering that the value of 
volumetric measurements of enhancing brain lesions are 
increasingly discussed (18), future manual detection and 
segmentation pose a tedious and time-consuming 
challenge, particularly with the growing use of multi-
sequence 3D imaging.  
In this study, we demonstrated the clinical value 
of a novel DropOut model for automatic detection and 
segmentation of brain metastases. This neural network has 
a unique advantage over other segmentation networks 
because it uses an input dropout layer; trained on a full set 
of four MRI input sequences, as well as every possible 
reduced subset of the input channels, thus simulating the 
scenario of missing MRI data during training.
Table 3: Detection accuracy and segmentation performance  
Network AUC ROC DICE Recall Precision FP (no size limit) FP (10 mm3 size limit) 
DeepLab V3 0.989±0.023 0.774±0.104 0.631±0.208 0.722±0.206 26.3±17.2 7.0±5.3 
DropOut 0.989±0.029 0.795±0.105 0.671±0.262 0.790±0.158 12.3±10.2 3.6±4.1 
P-value 0.620 0.017 0.167 0.095 <0.001 <0.001 
All metrics except AUC ROC were estimated using a probability threshold of 0.87 for the DeepLab V3 model, and 0.76 for the 
DropOut model 
Figure 3: ROC curves with 95% confidence interval 
(shaded area) averaged across all 55 test cases for the [A] 
DeepLab V3 model and the [B] DropOut method. The 
area under the ROC curve was 0.989 (ranging from 0.896 
to 1.000) for the DeepLab V3 model, and 0.989 (ranging 
from 0.845 to 1.000) for the DropOut model. 
Consequently, the resulting DropOut model can return a 
model output (probability map) regardless of missing 
sequences. The accuracy of the DropOut model in 
detecting metastatic voxels in the brain, as measured by 
the AUC, is equivalent to that of the state-of-the-art 
DeepLab V3 neural network trained on the specific subset 
of sequences in our test set. However, our results indicate 
that the proposed model is superior to the DeepLab V3 in 
terms of segmentation performance, as measured by the 
Dice score, and at the same time returning significantly 
fewer FP.  This generalization was also achieved despite 
differences in the patient demographics between the 
training and test sets, with more frequent representation 
of lung and melanoma metastases in the test set.  Finally, 
we would like to emphasize that the DropOut method does 
not require re-training for another subset of imaging 
sequences that might be acquired in another institution. 
The neural networks used in this study were 
based on the DeepLab V3 architecture, which is currently 
considered as one of the most robust neural networks for 
image-based semantic segmentation. The key difference 
of the DeepLab V3 compared with other relevant 
architectures is its reliance on atrous (or dilated) 
convolutions. By using atrous convolutional layers, our 
network has a very large receptive field, thereby 
incorporating greater spatial context. This approach may 
be key to enabling the network to identify local features as 
well as global contexts, i.e. identifying brain regions, which 
could enhance the network's decision-making process on 
similar local features. 
 In our study, the networks’ performance was 
tested on multi-center data, representing an essential step 
towards understanding the generalizability and clinical 
value of the proposed neural network. In this sense, it 
represents a logical extension of our prior single-center 
study on this topic ((15).  No previous studies have 
evaluated deep learning for brain metastasis detection 
using multi-center data. Other single-center studies, such 
as Liu et al. (13) and Charron et al. (14), have recently 
shown that deep neural networks can detect and segment 
brain metastases with high accuracy and performance, 
reporting results comparable to that of the current study. 
The latter study also demonstrated that a deep neural 
network trained on multi-sequence MRI data 
outperformed single contrast networks. 
In general, the two most commonly used MRI 
sequences for assessing brain metastases are post-Gd T1-
weighted and T2-weighted FLAIR. The post-Gd 3D T1-
weighted, high-resolution isotropic sequence is most 
crucial (19) and can be acquired by fast spin-echo or 
gradient-echo techniques. The 3D T1-weighted gradient-
echo sequences (e.g. IR-FSPGR, BRAVO, MPRAGE) are 
broadly used because they create isotropic T1-weighted 
images with excellent grey-white matter differentiation 
but are limited by lower contrast conspicuity and a lack of 
blood vessel suppression. The 3D fast spin-echo 
techniques (e.g. CUBE, SPACE, VISTA) are relatively newer 
techniques optimized for isotropic high-resolution 3D 
imaging of T1-weighted, T2-weighted, or FLAIR images; 
and have the advantage of blood vessel suppression. For 
this study, post-Gd T1-weighted 3D fast spin-echo, pre- 
and post-Gd T1-weighted 3D axial IR-FSPGR, and 3D FLAIR 
sequences were used as input to train the neural network. 
While these sequences are widely used for imaging brain 
metastases, they are not compulsory. Variations in 
sequences and acquisition parameters among different 
institutions also frequently are present. For instance, 2D 
FLAIR (with thicker slice and non-isotropic voxels) may be 
acquired instead of 3D FLAIR. In clinical practice, it is also 
not unusual to omit sequences owing to patients’ safety or 
Figure 4: Boxplot showing the resulting [A] Dice score, as well as the number of false positive [B] without and [C] with 
a lesion-size limit of 10 mm3, as determined from the segmentation probability maps produced by the DeepLab model 
(blue) and the in-house DropOut method (green). 
comfort. Therefore, it is imperative to design a robust and 
versatile neural network that can accommodate missing 
sequences while maintaining good performance. 
While this study shows a high accuracy using the 
DropOut model for detecting and segmenting brain 
metastases, the results should be interpreted in light of the 
limited sample size and the homogeneity of the test 
cohort. Patients included in the test set were all scheduled 
for SRS, which generally presents with fewer and larger 
metastases, which in turn may be easier for the network to 
predict. This hypothesis is supported by observations 
made in our previous study, in which the tested neural 
network showed higher accuracy in patients with 3 or less 
metastases compared to patients with >3 metastases (15). 
However, a total of nine patients in the current test set 
presented with >3 small metastases, for which the 
DropOut model still demonstrated a high accuracy and 
performance, equivalent to the average metrics for all 
lesions.  
 
In conclusion, this study demonstrates that the DropOut 
method, utilizing a pulse sequence level dropout layer, 
thus being trained on all possible combinations of 
multiple MRI sequences, can detect and segment brain 
metastases with high accuracy, even when the test cohort 
is missing input data.  This is likely of value for 
generalizing deep learning models for use in multiple 
different imaging sites. 
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